Hormone therapy (HRT/MHT) has had a complicated history. Here is what current evidence shows.

The WHI reanalysis — what actually changed:

The 2002 Women's Health Initiative findings caused millions of women to stop HRT. But 18-year cumulative follow-up (Manson et al., JAMA 2017; 2018) showed:

  • All-cause, cardiovascular, and cancer mortality: NO statistically significant difference between HT and placebo (HR 0.99, 95% CI 0.94-1.03)
  • Estrogen-alone (women with prior hysterectomy): NO increased breast cancer risk — in fact, a trend toward reduced incidence
  • Timing confirmed: women initiating HT within 10 years of menopause had more favorable outcomes
  • In February 2026, the FDA removed 'black box' warnings from most HT products

Absolute risk perspective (BMJ Harper et al., 2024):

  • The absolute risk of breast cancer with estrogen-plus-progestogen HRT is fewer than 1 additional case per 1,000 women per year of use
  • For estrogen-alone therapy, no increased risk was found across all follow-up periods
  • This places HRT's risk profile in the same range as many OTC medications

Current clinical recommendations (NICE updated April 2026, The Menopause Society, Endocrine Society):

  • HRT is first-line for moderate-severe vasomotor symptoms — Cochrane (Grant et al., 2019) confirms ~75% reduction in hot flash frequency vs placebo
  • For women under 60 or within 10 years of menopause, benefits outweigh risks — this is the 'window of opportunity' supported by the WHI reanalysis
  • For premature ovarian insufficiency (under 40), HRT is strongly recommended; benefits significantly outweigh risks in this population
  • Low-dose oral estradiol (0.5 mg/day): a randomized trial (JAMA, n=225 perimenopausal/postmenopausal women) found it reduced VMS frequency by 52.9% vs 28.6% placebo at 8 weeks
  • Transdermal estrogen (patch, gel) has lower blood clot risk than oral
  • Compounded bioidentical hormones are NOT recommended — lack FDA regulation

Key NICE 2026 updates:

  • Do NOT use FSH testing to diagnose menopause in women aged 45+ with typical symptoms — diagnosis is clinical
  • HRT should not be routinely offered solely for cardiovascular prevention
  • CBT is recommended for low mood, anxiety, and hot flash bother

⚠️ Every woman's situation is unique. Discuss your personal risk factors with a healthcare provider. Not all doctors are equally informed about latest evidence — seek a specialist if needed.